Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW Panel Initiates Discussions on Whether to Lift Ban on Export of Blood Products
March 17, 2017
- AMED Begins Taking Applications for Funding for Drug Discovery Environments
March 17, 2017
- Optimal Use Guidelines for Additional Indications to Be Reported to Chuikyo after Issuance
March 16, 2017
- Chuikyo Begins Debate on Gap-Year Price Revisions; Industry Frets Advance Announcement of Discrepancy Threshold
March 16, 2017
- Chuikyo Subcommittee OKs 5-Scale Rating for Cost Effective Assessments
March 16, 2017
- Spontaneous Reporting Required Even When Causal Relationship Is Unclear: MHLW
March 16, 2017
- Chuikyo Approves Optimal Use Promotion Guidelines for Repatha, Praluent
March 16, 2017
- Ex-Minister Tamura, 17 Healthcare Leaders to Launch Study Group
March 15, 2017
- MHLW to Up Ante on Drug Distribution, Launch Panel on March 29: Minister
March 15, 2017
- PMDA’s FY2017 Project Plan Sets Higher Goal for Standard Product Review
March 15, 2017
- PMDA Approves Draft Budget for FY2017
March 15, 2017
- PMDA’s Steering Committee Discusses Fines, Regulatory Revision in Wake of Kaketsuken Scandal
March 15, 2017
- Celgene Faces Biz Improvement Order over Delays in Side Effect Reporting
March 15, 2017
- Tokyo, Osaka Govts Issue Biz Improvement Order to Dealers over Fake Harvoni
March 14, 2017
- Orphan Status Withdrawn for 4 Flu Vaccines: MHLW Notification
March 13, 2017
- MHLW to Stockpile Enough Avigan for 30,000 Persons
March 13, 2017
- Drug Prices Should Be Raised for Products with Good Outcomes: Shiozaki
March 10, 2017
- Change Necessary for Ethical Drug Distribution Rules, Shiozaki Says after Fake Harvoni Fuss
March 10, 2017
- Reference Pricing on Agenda for CEFP Social Security Working Group
March 10, 2017
- NIBIOHN Looks to Spur Next-Gen Drug Development with Unique Antibody Techs, Joins Hands with 10 Companies
March 9, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…